Table 1. Clinical characteristics of patients (n=84).
| Gender Male/Female | 30/54 |
|---|---|
| Age (years) Median (range) | 69 (49–99) |
| Hemoglobin (g/dL) | |
| ≥10 | 31 (39%) |
| 8–9.9 | 33 (41%) |
| <8 | 16 (20%) |
| Platelets (x109/L) | |
| ≥100 | 29 (36%) |
| 50–99 | 22 (27%) |
| <50 | 30 (37%) |
| Leukocytes (x109/L) | |
| ≥1.5 | 76 (95%) |
| <1.5 | 4 (5%) |
| WHO classification (n (%)) | |
| RA | 1 (1%) |
| RCMD | 18 (22%) |
| RAEB1 | 21 (25%) |
| RAEB2 | 19 (23%) |
| 5q- | 2 (2%) |
| CMML | 7 (8%) |
| MDS-U | 5 (6%) |
| MDS/AML | 11 (13%) |
| Cytogenetic risk | |
| Very good | 2 (2%) |
| Good | 41 (49%) |
| Intermediate | 13 (16%) |
| Poor | 10 (12%) |
| Very poor | 18 (21%) |
| IPSS-R category | |
| Very low | 2 (2%) |
| Low | 15 (18%) |
| Intermediate | 20 (24%) |
| High | 23 (27%) |
| Very high | 21 (25%) |
| Unclassified | 3 (4%) |
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; IPSS-R, Revised International Prognostic Score System; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; 5q-, MDS with isolated 5q deletion; MDS-U: myelodysplastic syndrome unclassified; WHO, World Health Organization.